Compare · ACRS vs ALDX
ACRS vs ALDX
Side-by-side comparison of Aclaris Therapeutics Inc. (ACRS) and Aldeyra Therapeutics Inc. (ALDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACRS and ALDX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ACRS is the larger of the two at $608.9M, about 6.2x ALDX ($98.3M).
- Over the past year, ACRS is up 194.3% and ALDX is down 34.6% - ACRS leads by 228.9 points.
- ACRS has been more active in the news (8 items in the past 4 weeks vs 2 for ALDX).
- ACRS has more recent analyst coverage (18 ratings vs 6 for ALDX).
- Company
- Aclaris Therapeutics Inc.
- Aldeyra Therapeutics Inc.
- Price
- $4.37+0.00%
- $1.75+7.72%
- Market cap
- $608.9M
- $98.3M
- 1M return
- -10.27%
- +0.87%
- 1Y return
- +194.28%
- -34.64%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2014
- News (4w)
- 8
- 2
- Recent ratings
- 18
- 6
Aclaris Therapeutics Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Aldeyra Therapeutics Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts.
Latest ACRS
- Director Molineaux Christopher P. converted options into 11,580 shares, increasing direct ownership by 20% to 69,536 units (SEC Form 4)
- Director Milano Vincent converted options into 11,580 shares, increasing direct ownership by 67% to 28,896 units (SEC Form 4)
- Director Mehra Anand converted options into 11,580 shares, increasing direct ownership by 2% to 726,403 units (SEC Form 4)
- Director Humphries William D. converted options into 11,580 shares, increasing direct ownership by 35% to 45,105 units (SEC Form 4)
- Director Schiff Andrew N converted options into 11,580 shares, increasing direct ownership by 83% to 25,540 units (SEC Form 4)
- Director Gowen Maxine converted options into 11,580 shares, increasing direct ownership by 53% to 33,334 units (SEC Form 4)
- Aclaris Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
- SEC Form 10-Q filed by Aclaris Therapeutics Inc.
Latest ALDX
- President and CEO Brady Todd C bought $418,450 worth of shares (250,000 units at $1.67), increasing direct ownership by 17% to 1,721,298 units (SEC Form 4)
- Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.
- SEC Form 10-Q filed by Aldeyra Therapeutics Inc.
- SEC Form DEFA14A filed by Aldeyra Therapeutics Inc.
- SEC Form DEF 14A filed by Aldeyra Therapeutics Inc.
- Aldeyra Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 8-K filed by Aldeyra Therapeutics Inc.
- SEC Form 4 filed by Brady Todd C
- Amendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.